Frank Vinluan from MedCity News - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation		AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia Med Flunks Phase 2 Test - 6 days ago ‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood Cancer - 7 days ago FDA Takes Step Toward Removal of Ineffective Decongestants From the Market - 9 days ago Private Equity Is Picking Up Biologics CDMO Avid Bioservices in $1.1B Acquisition - 10 days ago Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M - 11 days ago Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - 12 days ago Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs - 13 days ago Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug - 13 days ago Protein-Design Startup Archon Adds $20M to Show How ‘Cages’ Can Change Antibody Drugs - 14 days ago Novo Nordisk GLP-1 Drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA Filings - 16 days ago Precision Oncology Startup Kivu Unveils $92M for More Stable & Durable ADC Cancer Drugs - 17 days ago Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder - 18 days ago Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy - 19 days ago AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition - 20 days ago Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications - 20 days ago Seaport Therapeutics Secures $225M for New Kind of Depression Drug - 21 days ago Septerna’s Upsized IPO Brings In $288M to Support a Pipeline of GPCR Drugs - 23 days ago Gates Foundation Joins Radiant Bio’s $35M Round for Antibody Drugs With ‘Better Grip’ - 24 days ago Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - 25 days ago Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D - 26 days ago Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer - 27 days ago How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come - 28 days ago Gilead Sciences Voluntarily Pulls Drug for Bladder Cancer After Trial Failure - about 1 month ago Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact With Orano - about 1 month ago Wearable Tumor-Zapping Medical Device Wins FDA Approval for Lung Cancer - about 1 month ago On Heels of Positive Parkinson’s Gene Therapy Data, MeiraGTx Looks Ahead to Pivotal Test - about 1 month ago Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition - about 1 month ago Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M - about 1 month ago J&J Backs Down From 340B Rebates, But Maintains They’re ‘Legally Permissible’ Per Statute - about 1 month ago Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M - about 1 month ago CBRE Report: Post-Pandemic Slowdown Now Evident in Oversupply of Biotech Labs - about 2 months ago Eli Lilly Plans $4.5B Medicine Foundry to Foster Innovations in Drug Manufacturing - about 2 months ago Metabolic Meds Biotech Kailera Launches With $400M for Next-Generation Weight-Loss Drugs - about 2 months ago Gene-Editing Biotech Prime Medicine Strikes Up Cell Therapy R&D Alliance With Bristol Myers Squibb - about 2 months ago Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs - 2 months ago 3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders - 2 months ago Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug - 2 months ago SEC Charges Ipsen Worker for Insider Trading Tied to $247M Epizyme Acquisition - 2 months ago Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug - 2 months ago Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study - 2 months ago A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets - 2 months ago Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas - 2 months ago Eli Lilly Moves Closer to Bringing Diabetes Patients a Once-Weekly Insulin Alternative - 2 months ago With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs - 2 months ago Illumina’s European Court Victory Can’t Salvage Grail Acquisition, But It Nullifies Hefty Fine - 3 months ago Highly Anticipated FDA Decision Comes Just in Time for Back-to-School Season - 3 months ago FDA Approves Emergent BioSolutions Vaccine as New Tool in Fight Against Mpox - 3 months ago Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline - 3 months ago FDA Rejection Delays Regeneron From Competing With J&J, Pfizer in Multiple Myeloma - 3 months ago Eli Lilly Drug Reduces Risk of Diabetes Onset, Building Case for Broader Use of the Therapy - 3 months ago